Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Trials and therapies in secondary progressive MS, simplified

Nature Reviews Neurology volume 15, pages 431–432 (2019)Cite this article

Subjects

The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391, 1263–1273 (2018).

    Article  CAS  Google Scholar 

  2. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann. Neurol. 58, 840–846 (2005).

    Article  Google Scholar 

  3. Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).

    Article  Google Scholar 

  4. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).

    Article  Google Scholar 

  5. Montalban, X. et al. Cladribine tablets added to IFN-beta in active relapsing MS: the ONWARD study. Neurol. Neuroimmunol. Neuroinflamm. 5, e477 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Neurotherapeutics, the University of Texas Southwestern Medical Center, Dallas, TX, USA

    Navid Manouchehri & Olaf Stüve

  2. Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Center, Dallas, TX, USA

    Olaf Stüve

Authors
  1. Navid Manouchehri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olaf Stüve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olaf Stüve.

Ethics declarations

Competing interests

O.S. serves on the editorial board of Therapeutic Advances in Neurological Disorders, has served on data monitoring committees for Genentech–Roche, Pfizer and TG Therapeutics without monetary compensation, has advised Celgene, EMD Serono, Genzyme and Serono, and has received grant support from Sanofi Genzyme. N.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manouchehri, N., Stüve, O. Trials and therapies in secondary progressive MS, simplified. Nat Rev Neurol 15, 431–432 (2019). https://doi.org/10.1038/s41582-019-0233-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0233-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing